Member Login
  1. Stocks
    2. /
  2. AstraZeneca PLC (LSE: AZN)
    3. /

LSE:AZN (AstraZeneca PLC)

About AZN

AstraZeneca is a biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Respiratory, Inflammation and Autoimmunity (RIA), Cardiovascular and Metabolic Disease (CVMD) and Oncology – as well as in Infection and Neuroscience.
Financial Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • AstraZeneca PLC (LSE: AZN) Latest News

    Investing Articles

    This UK stock looks pretty cheap to me

    | Gordon

    This Fool is always on the hunt for value, and with plenty of potential for growth, this UK stock ticks…

    Read more »

    Edinburgh Cityscape with fireworks over The Castle and Balmoral Clock Tower
    Investing Articles

    My favourite UK share on the entire LSE has fallen 5% in a week! Time to buy?

    | Harvey Jones

    Harvey Jones has waited for years to buy this brilliant UK share. Has the recent stock market dip finally handed…

    Read more »

    Investing Articles

    FTSE 100 investors should pay attention to these 4 things in September 2024

    | Charlie Carman

    Charlie Carman explores four key factors for UK investors to monitor this month that will influence the future direction of…

    Read more »

    Investing Articles

    4 stocks that might power the FTSE 100 towards 10,000

    | John Fieldsend

    The FTSE 100 has been flirting with its all-time high again. Could it break through and hit that magical 10,000…

    Read more »

    Investing Articles

    As AstraZeneca reaches a 52-week high, is this still a top UK stock to consider?

    | Ben McPoland

    Ben McPoland takes a look at the largest UK stock by market cap to assess whether it might be overvalued…

    Read more »

    Silhouette of a bull standing on top of a landscape with the sun setting behind it
    Investing Articles

    5 FTSE stocks Fools think will lead the next bull market charge

    | The Motley Fool Staff

    Savvy Fools will know the time to be buying the best FTSE stocks isn’t when a new bull market is…

    Read more »

    Person holding magnifying glass over important document, reading the small print
    Investing Articles

    Up 38% from its 12-month low, how can AstraZeneca’s share price still look cheap?

    | Simon Watkins

    Despite its big rise over the year, AstraZeneca’s share price still looks very undervalued to me, supported by strong H1…

    Read more »

    Investing Articles

    AstraZeneca hits £200bn as its share price soars. Can I afford to miss out?

    | Alan Oscroft

    The AstraZeneca share price is up 17% so far this year. But now the firm has broken the £200bn barrier,…

    Read more »

    Investing Articles

    If I had £5k to invest in August, I’d buy these 2 top FTSE 100 stocks

    | Ben McPoland

    This writer highlights a growth-oriented pair of FTSE 100 stocks that he thinks look poised to deliver long-term growth for…

    Read more »

    Young mixed-race woman jumping for joy in a park with confetti falling around her
    Investing Articles

    No savings at 40? I’d buy cheap UK shares to retire richer

    | Zaven Boyrazian, MSc

    Buying cheap UK shares can have a profound impact on long-term wealth, even when starting later in life. Zaven Boyrazian…

    Read more »

    Investing Articles

    AstraZeneca, a mega-cap growth stock that just got cheaper!

    | Dr. James Fox

    Our writer takes a closer look at this growth stock -- which also happens to be the largest company of…

    Read more »

    Engineer Project Manager Talks With Scientist working on Computer
    Investing Articles

    The AstraZeneca share price dips as the company raises full-year guidance!

    | Kevin Godbold

    AstraZeneca's biopharmaceutical business is delivering ongoing growth, so share price weakness now may be a buying opportunity.

    Read more »